The CRF1 receptor antagonist, DMP695, abolishes activation of locus coeruleus noradrenergic neurones by CRF in anesthetized rats

European Journal of Pharmacology

Volumn 464, Issue 2-3, 2003, Pages 127-133

  Lejeune, Françoise ^a   Millan, Mark J ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Corticotropin releasing factor (CRF); DMP695; Locus coeruleus; Unit activity

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DMP 695; N (2 CHLORO 4,6 DIMETHYLPHENYL) 1 (1 METHOXYMETHYL 2 METHOXYETHYL) 6 METHYL 1H 1,2,3 TRIAZOLO[4,5 C]PYRIDIN 4 AMINE MESYLATE; UNCLASSIFIED DRUG; (N (2 CHLORO 4,6 DIMETHYLPHENYL) 1 (1 METHOXYMETHYL) (2 METHOXYMETHYL) 6 METHYL 1H 1,2,3 TRIAZOLO(4,5 C)PYRIDIN 4 AMINE) MESYLATE; (N-(2-CHLORO-4,6-DIMETHYLPHENYL)-1-(1-METHOXYMETHYL)-(2-METHOXYMETHYL)-6-METHYL-1H-1,2,3-TRIAZOLO(4,5-C)PYRIDIN-4-AMINE) MESYLATE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CRF RECEPTOR TYPE 1; NORADRENALIN; PYRIDINE DERIVATIVE;

ANESTHESIA; ANIMAL CELL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ELECTRICITY; LOCUS CERULEUS; MALE; NONHUMAN; NORADRENERGIC NERVE; PERIKARYON; PRIORITY JOURNAL; RAT; ANIMAL; CYTOLOGY; DRUG ANTAGONISM; ELECTROPHYSIOLOGY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; NERVE CELL; PHYSIOLOGY; WISTAR RAT;

ADRENERGIC ALPHA-AGONISTS; ANESTHESIA; ANIMALS; CLONIDINE; CORTICOTROPIN-RELEASING HORMONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; INJECTIONS, INTRAVENTRICULAR; LOCUS COERULEUS; MALE; NEURONS; NOREPINEPHRINE; PYRIDINES; RATS; RATS, WISTAR; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE;

EID: 0037454130     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01383-9     Document Type: Article

References (47)

1. Aghajanian G.K., Cedarbaum J.M., Wang R.Y. Evidence for a norepinephrine-mediated collateral inhibition of locus coeruleus neurons. Brain Res. 136:1977;570-577.
2. 1) receptor antagonist. ACS National Meeting, Boston, MA, Aug. 23-27, 1998. Abstr. Med. vol. 134:1998.
3. Borsody M.K., Weiss J.M. Influence of corticotropin-releasing hormone on electrophysiological activity of locus coeruleus neurons. Brain Res. 724:1996;149-168.
4. Bundey R.A., Kendall D.A. Inhibition of receptor-mediated calcium responses by corticotropin-releasing hormone in the CATH a cell line. Neuropharmacology. 38:1999;39-47.
5. Charney D.S., Bremmer J.D., Redmond D.E. Noradrenergic neural substrates for anxiety and fear. Clinical associations based on preclinical research. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;387-395 Raven Press, New York.
6. Chen Y., Brunson K.L., Müller M.B., Cariaga W., Baram T.Z. Immunocytochemical distribution of corticotropin-releasing hormone receptor Type-1 (CRF1)-like immunoreactivity in the mouse brain: light microscopy analysis using an antibody directed against the C-terminus. J. Comp. Neurol. 420:2000;305-323.
7. Conti L.H., Youngblood K.L., Printz M.P., Foote S.L. Locus coeruleus electrophysiological activity and responsivity to corticotropin-releasing factor in inbred hypertensive and normotensive rats. Brain Res. 774:1997;27-34.
8. Curtis A.L., Lechner S.M., Pavcovich L.A., Valentino R.J. Activation of the locus coeruleus noradrenergic system by intracoerulear microinfusion of corticotropin-releasing factor: effects on discharge rate, cortical norepinephrine levels and cortical electroencephalographic activity. J. Pharmacol. Exp. Ther. 281:1997;163-172.
9. De Souza E.B. Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinology. 20:1995;789-819.
10. Emoto H., Koga C., Ishii H., Yokoo H., Yoshida M., Tanaka M. A CRF antagonist attenuates stress-induced increases in noradrenaline turnover in extended brain regions in rats. Brain Res. 627:1993;171-176.
11. Florin-Lechner S.M., Druhan J.P., Aston-Jones G., Valentino R.J. Enhanced norepinephrine release in prefrontal cortex with burst stimulation of the locus coeruleus. Brain Res. 742:1996;89-97.
12. Gilligan P.J., Robertson D.W., Zaczek R. Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. J. Med. Chem. 43:2000;1641-1660.
13. 2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse. 36:2000;205-221.
14. Griebel G., Simiand J., Steinberg R., Jung M., Gully D., Roger P., Geslin M., Scatton B., Maffrand J.-P., Soubrié P. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4- methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor1 receptor antagonist: II. Characterization in rodent models of stress-related disorders. J. Pharmacol. Exp. Ther. 301:2002;333-345.
15. Grigoriadis D.E., Haddach M., Ling N., Saunders J. The CRF receptor: structure, function and potential for therapeutic intervention. Curr. Med. Chem. 1:2001;63-97.
16. Grosjean-Piot G., Burgevin M.C., Achard D., Pauchet C., Betschart J., Imperato A., Dubroeucq M.C. In vitro and in vivo characterization of CP-154,526, a non-peptide CRF1 receptor antagonist with partial agonist properties. Eur. Neuropsychopharmacol. 7:1997;S276-S277.
17. Harro J., Oreland L. Depression as a spreading adjustment disorder of monoaminergic neurons: a case for primary implication of the locus coeruleus. Brain Res. Rev. 38:2001;79-128.
18. 1 receptor antagonist. J. Med. Chem. 43:2000;449-456.
19. Isogawa K., Akiyoshi J., Hikichi T., Yamamoto Y., Tsutsumi T., Nagayama H. Effect of corticotropin releasing factor receptor 1 antagonist on extracellular norepinephrine, dopamine and serotonin in hippocampus and prefrontal cortex of rats in vivo. Neuropeptides. 34:2000;234-239.
20. Jedema H.P., Grace A.A. Effect of corticotropin releasing hormone (CRH) on electrophysiological properties of locus coeruleus neurons recorded in vitro. Soc. Neurosci. 26:2000;1433.
21. Kawahara H., Kawahara Y., Westerink B.H.C. The role of afferents to the locus coeruleus in the handling stress-induced increase in the release of noradrenaline in the medial prefrontal cortex: a dual-probe microdialysis study in the rat brain. Eur. J. Pharmacol. 387:2000;274-279.
22. 1A receptors. Eur. J. Neurosci. 12:2000;1-11.
23. Mar Sanchez M., Young L.J., Plotsky P.M., Insel T.R. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J. Comp. Neurol. 408:1999;365-377.
24. Menzaghi F., Howard R.L., Heinrichs S.C., Vale W., Rivier J., Koob G.F. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J. Pharmacol. Exp. Ther. 269:1994;564-572.
25. Millan M.J., Lejeune F., Gobert A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J. Psychopharmacol. 14:2000;114-138.
26. 2-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. J. Pharmacol. Exp. Ther. 295:2000;1206-1222.
27. 1 antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology. 25:2001;585-600.
28. Mitchell A.J. The role of corticotropin releasing factor in depressive illness: a critical review. Neurosci. Biobehav. Rev. 22:1998;635-651.
29. Okuyama S., Chaki S., Kawashima N., Suzuki Y., Ogawa S.-I., Nakazato A., Kumagai T., Okubo T., Tomisawa K. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J. Pharmacol. Exp. Ther. 289:1999;926-935.
30. Page M.E., Abercrombie E.D. Discrete local application of corticotropin-releasing factor increases locus coeruleus discharge and extracellular norepinephrine in rat hippocampus. Synapse. 33:1999;304-313.
31. Palamarchouk V.S., Zhang J.-J., Zhou G., Swiergiel A.H., Dunn A.J. Hippocampal norepinephrine-like voltammetric responses following infusion of corticotropin-releasing factor into the locus coeruleus. Brain Res. Bull. 51:2000;319-326.
32. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, Sydney.
33. Sauvage M., Steckler T. Detection of corticotropin-releasing hormone receptor 1 immunoreactivity in cholinergic, dopaminergic and noradrenergic neurons of the murine basal forebrain and brainstem nuclei-potential implication for arousal and attention. Neuroscience. 104:2001;643-652.
34. Sawchenko P.E., Imaki T., Potter E., Kovacs K., Imaki J., Wale W. The functional neuroanatomy of corticotropin-releasing factor. Ciba Found. Symp. 172:1993;5-21.
35. Schulz D.W., Mansbach R.S., Sprouse J., Baselton J.P., Collins J., Corman M., Dunaiskis A., Faraci S., Schmidt A.W., Seeger T., Seymour P., Tingley F.D. III, Winston E.N., Chen Y.L., Heym J. CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc. Natl. Acad. Sci. U. S. A. 93:1996;10477-10482.
36. Smagin G.N., Swiergiel A.H., Dunn A.J. Corticotropin-releasing factor administered into the locus coeruleus, but not the parabrachial nucleus, stimulates norepinephrine release in the prefrontal cortex. Brain Res. Bull. 36:1995;71-76.
37. Smagin G.N., Zhou J., Harris R.B.S., Ryan D.H. CRF receptor antagonist attenuates immobilization stress-induced norepinephrine release in the prefrontal cortex in rats. Brain Res. Bull. 42:1997;431-434.
38. Smith G.W., Aubry J.-M., Dellu F., Contarino A., Bilezikjian L.M., Gold L.H., Chen R., Marchuk Y., Hauser C., Bentley C.A., Sawchenko P.E., Koob G.F., Vale W., Lee K.-F. Corticotropin releasing factor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron. 20:1998;1093-1102.
39. Steckler T., Holsboer F. Corticotropin-releasing hormone receptor subtypes and emotion. Biol. Psychiatry. 46:1999;1480-1508.
40. Suaud-Chagney M.F., Mermet C., Gonon F. Electrically evoked noradrenaline release in the rat hypothalamic paraventricular nucleus studied by in vivo electrochemistry: characterization and facilitation by increasing the stimulation frequency. Neuroscience. 34:1990;411-422.
41. Sullivan G.M., Coplan J.D., Kent J.M., Gorman J.M. The noradrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias. Biol. Psychiatry. 46:1999;1205-1218.
42. Swiergiel A.H., Takahashi L.K., Rubin W.W., Kalin N.H. Antagonism of corticotropin-releasing factor receptors in the locus coeruleus attenuates shock-induced freezing in rats. Brain Res. 587:1992;263-268.
43. Valentino R.J., Van Bockstaele E. Opposing regulation of the locus coeruleus by corticotropin-releasing factor and opioids. Psychopharmacology. 158:2001;331-342.
44. Valentino R.J., Page M., Van Bockstaele E., Aston-Jones G. Corticotropin-releasing factor innervation of the locus coeruleus region: distribution of fibers and sources of input. Neuroscience. 48:1992;689-705.
45. Valentino R.J., Rudoy C., Saunders A., Liu X.-B., Van Bockstaele E.J. Corticotropin-releasing factor is preferentially colocalized with excitatory rather than inhibitory amino acids in axon terminals in the peri-locus coeruleus region. Neuroscience. 106:2001;375-384.
46. Van Bockstaele E.J., Bajic D., Proudfit H., Valentino R.J. Topographic architecture of stress-related pathways targeting the noradrenergic locus coeruleus. Physiol. Behav. 73:2001;273-283.
47. Zhang J.-J., Swiergiel A.H., Palamarchouk V.S., Dunn A.J. Intracerebroventricular infusion of CRF increases extracellular concentrations of norepinephrine in the hippocampus and cortex as determined by in vivo voltammetry. Brain Res. Bull. 47:1998;277-284.